On patients, prescriptions, and profits

Nancy MP King

DOI: 10.20529/IJME.2018.009


Abstract

Sharon Batt’s study of the relationship between breast cancer advocacy groups and the pharmaceutical industry in Canada is exhaustively researched, formidably detailed, analytically nuanced, riveting, and all too familiar. With over 50 pages of endnotes and an index of more than 30 pages, this book will satisfy the most demanding policy wonks. At the same time, however, extensive quotations from her interviews of key actors in the advocacy movement help to make both the policy narrative and the arguments on all sides of the issues understandable and accessible. Perhaps most importantly for many readers, although focused on Canada, Batt’s analysis of the changes in governmental priorities, drug costs, and patients’ expectations clearly has applicability all around the globe.

Full Text

HTML PDF

Keywords

N/A

Refbacks

There are currently no refbacks.